Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are commonly used for the treatment of anemia due to chronic kidney disease (CKD) and end stage renal disease (ESRD). Patients often lack an understanding of the potential risks and benefits of ESAs, despite government mandated education on this t...

Descripción completa

Detalles Bibliográficos
Autores principales: Beach, Lauren B., Wild, Marcus, Ramachandran, Gowri, Ikizler, H. Omer, Cavanaugh, Kerri L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949884/
https://www.ncbi.nlm.nih.gov/pubmed/27430294
http://dx.doi.org/10.1186/s12882-016-0301-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949884/
https://www.ncbi.nlm.nih.gov/pubmed/27430294
http://dx.doi.org/10.1186/s12882-016-0301-z

Ejemplares similares